Platinum drugs and DNA repair mechanisms in lung cancer - PubMed (original) (raw)
Review
. 2014 Jan;34(1):493-501.
Affiliations
- PMID: 24403507
Review
Platinum drugs and DNA repair mechanisms in lung cancer
Laura Bonanno et al. Anticancer Res. 2014 Jan.
Abstract
The standard first-line treatment for around 80% of newly-diagnosed advanced non-small cell lung cancer (NSCLC) is chemotherapy. Currently, patients are allocated to chemotherapy on the basis of clinical conditions, comorbidities and histology. If feasible, platinum-based chemotherapy is considered as the most efficacious option. Due to the heterogeneity in terms of platinum-sensitivity among patients with NSCLC, great efforts have been made in order to identify molecular predictive markers of platinum resistance. Based on the mechanism of action of platinum, several components of DNA repair pathways have been investigated as potential predictive markers. The main DNA repair pathways involved in the repair of platinum-induced DNA damage are nucleotide excision repair and homologous recombination. The most studied potential predictive markers of platinum-sensitivity are Excision Repair Cross Complementing-1 (ERCC1) and Brest Cancer Type-I Susceptibility protein (BRCA1); however, increasing biological knowledge about DNA repair pathways suggests the potential clinical usefulness of integrated analysis of multiple DNA repair components.
Keywords: DNA repair mechanisms; Platinum; lung cancer; predictive markers; review.
Similar articles
- Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
Saldivar JS, Wu X, Follen M, Gershenson D. Saldivar JS, et al. Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S56-71. doi: 10.1016/j.ygyno.2007.07.043. Epub 2007 Sep 19. Gynecol Oncol. 2007. PMID: 17884153 Review. - A review of excision repair cross-complementation group 1 in colorectal cancer.
Bohanes P, Labonte MJ, Lenz HJ. Bohanes P, et al. Clin Colorectal Cancer. 2011 Sep;10(3):157-64. doi: 10.1016/j.clcc.2011.03.024. Epub 2011 Apr 28. Clin Colorectal Cancer. 2011. PMID: 21855036 Review. - Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC. Zhou W, et al. Clin Cancer Res. 2004 Aug 1;10(15):4939-43. doi: 10.1158/1078-0432.CCR-04-0247. Clin Cancer Res. 2004. PMID: 15297394
Cited by
- Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh.
Bushra MU, Rivu SF, Sifat AE, Nahid NA, Ahmed MU, Al-Mamun MMA, Apu MNH, Islam MS, Islam MR, Islam MS, Hasnat A. Bushra MU, et al. Mol Biol Rep. 2020 Sep;47(9):7073-7082. doi: 10.1007/s11033-020-05771-2. Epub 2020 Sep 3. Mol Biol Rep. 2020. PMID: 32880833 - Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients.
Zhang S, He L, Dai N, Guan W, Shan J, Yang X, Zhong Z, Qing Y, Jin F, Chen C, Yang Y, Wang H, Baugh L, Tell G, Wilson DM 3rd, Li M, Wang D. Zhang S, et al. Oncotarget. 2016 Nov 22;7(47):77482-77494. doi: 10.18632/oncotarget.13030. Oncotarget. 2016. PMID: 27813497 Free PMC article. - Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer.
Owen DH, Williams TM, Bertino EM, Mo X, Webb A, Schweitzer C, Liu T, Roychowdhury S, Timmers CD, Otterson GA. Owen DH, et al. Lung Cancer. 2019 Aug;134:167-173. doi: 10.1016/j.lungcan.2019.06.017. Epub 2019 Jun 17. Lung Cancer. 2019. PMID: 31319977 Free PMC article. - Chinese C allele carriers of the ERCC5 rs1047768 polymorphism are more sensitive to platinum-based chemotherapy: a meta-analysis.
Xu M, Liu Y, Li D, Wang X, Liang S, Zhang G, Yang X. Xu M, et al. Oncotarget. 2017 Jul 4;9(1):1248-1256. doi: 10.18632/oncotarget.18981. eCollection 2018 Jan 2. Oncotarget. 2017. PMID: 29416691 Free PMC article. - Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer.
Gower A, Wang Y, Giaccone G. Gower A, et al. J Mol Med (Berl). 2014 Jul;92(7):697-707. doi: 10.1007/s00109-014-1165-y. Epub 2014 May 23. J Mol Med (Berl). 2014. PMID: 24852181 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous